Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lymphoma × Tolbutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Rituximab 58 Cyclophosphamide 47 fludarabine phosphate 23 fludarabine 20 Filgrastim 20 Methotrexate 18 Melphalan 18 Radiotherapy 17 Etoposide 17 Vincristine 16 Doxorubicin 15 Cytarabine 14 Whole-Body Irradiation 13 Tacrolimus 13 Prednisone 13 Peripheral Blood Stem Cell Transplantation 13 Mycophenolic Acid 13 Cyclosporine 13 Antilymphocyte Serum 13 Gemcitabine 12 Lenalidomide 11 Busulfan 10 Bortezomib 9 Granulocyte Colony-Stimulating Factor 8 Dexamethasone 8 Cord Blood Stem Cell Transplantation 8 sargramostim 7 Vorinostat 7 Methylprednisolone 7 Carmustine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01185548 2018-10-19

JZAR

Eli Lilly and Company

Phase 1 Terminated

4 enrolled 8 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡